personalized-medicine
(24)
The Second Blood Test Is the Point
Superpower sells 150-plus biomarkers, an AI-assisted plan and a second look at your blood. The interesting product is not the test. It is the feedback loop after it.
Amwise Diagnostic PTE. LTD.
Amwise Diagnostic is a Singapore- and Taipei-based cancer genomics company behind RecurIndex, a multi-gene test built specifically on the genomes of Asian breast cancer patients. It reads a tumor's genetic profile alongside clinical factors to estimate the five-year risk of local recurrence and distant metastasis, helping physicians and patients decide whether chemotherapy or radiotherapy is actually needed - and helping many avoid treatment they don't.
BostonGene
BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
Oova
Oova is a New York-based women's health company that brings lab-grade hormone testing into the home. Founded in 2017 as a Mount Sinai spinout by Dr. Aparna (Amy) Divaraniya, Oova combines urine test strips, smartphone scanning, and AI to quantitatively measure LH, E3G (estrogen metabolite), and PdG (progesterone metabolite), giving women personalized daily insights for fertility, PCOS, cycle health, and perimenopause. The FDA-registered platform is used by consumers and integrated with hundreds of fertility and women's health clinics through a HIPAA-compliant provider dashboard.
ARNA Genomics US Inc.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.
Cipherome, Inc.
Cipherome is a San Jose-based clinical genomics and bioinformatics company on a mission to find the drug that works for each individual. Its no-code platform COMPASS lets researchers transform, query, and analyze massive clinical and genomic datasets - like the 500,000-participant UK Biobank - without writing code, while its Xentinel platform uses explainable AI to predict and reduce adverse drug reactions. Backed by roughly $16-23M through a Series B, the 12-person team pairs Silicon Valley software with Seoul National University biomedical-informatics research.
Human Longevity, Inc.
Human Longevity, Inc. is a San Diego- and South San Francisco-based genomics and precision-health company founded in 2013 by genome-sequencing pioneer J. Craig Venter, Peter Diamandis, and Robert Hariri. It pairs clinical-grade whole genome sequencing with whole-body MRI, hundreds of blood biomarkers, and AI analytics - delivered through its Health Nucleus platform - to detect cancer, cardiovascular disease, and other age-related conditions before symptoms appear. After a decade building one of the world's largest longitudinal genotype-phenotype datasets, the company in 2026 launched a $599 clinical-grade whole genome report and spun out Human Life Foundation Models, Inc. to build large-scale AI foundation models for longevity science.
Mylene Yao
Mylene Yao is co-founder, director, and CEO of Univfy, a Los Altos-based healthcare AI company that builds personalized IVF success prediction models. A board-certified OB/GYN trained at the University of Toronto, McGill, and Harvard, she was a Stanford faculty member running an NIH-funded embryo development lab before spinning her prediction research out with statistician Wing H. Wong. Univfy's models tell patients their individual odds of having a baby with IVF, and pair the prediction with financing so more people can actually pursue treatment.
NeuroAge Therapeutics
NeuroAge Therapeutics is a San Francisco tech-bio company that measures how old your brain actually is - and tries to make it younger. Founded in 2022 by physician-scientist Dr. Christin Glorioso, the company's flagship NeuroAge Test blends brain MRI, cognitive games, proprietary RNA blood biomarkers, and genetic screening into a single 'brain age' score that aims to flag dementia risk up to 30 years before symptoms appear. The longer-term goal is bolder: small-molecule drugs that reprogram aging neurons back toward a younger state.
The Lanby
The Lanby is a membership-based, hospitality-led primary care practice in New York City that reimagines concierge medicine for a modern, prevention-minded patient. Founded in 2021 by breast cancer survivor Chloe Harrouche, it pairs every member with a dedicated care team - a lead physician, wellness advisor, medical assistant, physician associate, and member advocate - to connect the dots across medicine, wellness, and care coordination. For a flat annual fee and no insurance friction, members get unlimited visits, advanced diagnostics with 85+ biomarkers, personalized care plans, and expedited specialist referrals.
ImpriMed, Inc.
ImpriMed is a Palo Alto-based precision medicine company using live-cell drug sensitivity testing and AI to predict how individual cancer patients - starting with dogs and cats - will respond to specific chemotherapy drugs. Founded in 2017 by Stanford engineering PhDs Sungwon Lim and Jamin Koo, ImpriMed serves a network of 250+ veterinary oncologists and is expanding its platform into human blood cancers and pharma CRO services.
OptraHEALTH
OptraHEALTH is a San Jose-based AI healthcare intelligence company that turns dense genomic and clinical data into plain conversation. Its patented HealthFAX platform and GeneFAX product line use conversational AI, natural language processing, and knowledge graphs to help labs, hospitals, payors, and patients navigate genetic testing, revenue cycle management, prior authorization, and clinical decisions - letting people ask their health data questions through chat, mobile, and voice interfaces.
Aihua Fu
Aihua Fu is a nanobiotechnologist and the co-founder, President and CEO of NVIGEN Inc., a San Jose nanobiotechnology company building molecularly engineered magnetic and fluorescent nanoparticles for cancer detection and personalized medicine. Trained as a chemist under Nobel-track nanoscience pioneer A. Paul Alivisatos at UC Berkeley and as a postdoc at Stanford, she turned quantum-dot and magnetic-bead research into commercial tools for liquid biopsy, cfDNA extraction, single-cell sequencing and circulating tumor cell capture. Her flagship NVIGEN X and NERNST-Seq platforms aim to read DNA, RNA, protein and cell signals together to predict cancer recurrence early and guide therapy.
I Peace, Inc.
I Peace, Inc. is a Palo Alto- and Kyoto-based biotech that mass-manufactures clinical-grade induced pluripotent stem cells (iPSCs) using a proprietary automated, closed-cassette platform. Founded in 2015 by Koji Tanabe - a co-author of the world's first human iPSC paper from Shinya Yamanaka's Nobel Prize-winning lab - the company operates as a CDMO supplying GMP-grade iPSCs to pharmaceutical companies, biotechs, and research institutions, and offers personal iPSC banking and longevity services that aim to make cell therapy affordable and accessible.
Bob Wassman
Dr. E. Robert (Bob) Wassman is Chief Medical Officer and Executive Vice President of Clinical Development at MARAbio, a Utah-based diagnostics company building a maternal blood test to identify an autoimmune subtype of autism. A board-certified pediatrician and medical geneticist with more than 40 years in the field, he has served as chief medical officer for a long roster of genetic-testing pioneers including Genzyme Genetics, Ambry Genetics, Rosetta Genomics and Good Start Genetics, repeatedly turning frontier laboratory technology into clinical service across reproductive medicine, cancer, and neurodevelopmental disability.
Nucleus Genomics
Nucleus Genomics is a New York-based consumer genomics company that sells a $399 at-home, clinical-grade whole-genome sequencing kit and a software platform that turns a person's full DNA sequence into readable reports on disease risk, carrier status, traits, and longevity. Founded in 2021 by Thiel Fellow Kian Sadeghi, Nucleus pairs whole-genome data with polygenic risk scores and lifestyle inputs to estimate risk for common, complex conditions. In 2025 it expanded into reproductive products - carrier screening, partner DNA alignment, and a controversial embryo-ranking tool, Nucleus Embryo - that put the company at the center of a public debate over the science and ethics of genetic selection.
One Health Company (FidoCure)
One Health Company, known to vets and pet parents as FidoCure, brings human-grade precision oncology to dogs. It sequences canine tumors, pinpoints cancer-driving mutations, and uses an AI engine (Fetch) trained on the world's largest structured canine cancer dataset to recommend targeted, FDA-approved therapies. Because dog and human cancers share genetics, the company is also building a comparative-oncology data asset that could accelerate cancer drug development for both species.
Progentec Diagnostics, Inc.
Progentec Diagnostics is an Oklahoma City company building blood-based biomarker tests and digital health tools for autoimmune diseases, starting with lupus. Its lead product, the aiSLE DX Flare Risk Index, uses an 11-biomarker algorithm to predict a lupus flare up to 12 weeks before it happens, giving rheumatologists a chance to intervene early. Spun out of research tied to the Oklahoma Medical Research Foundation, the company pairs lab science with patient-facing tools like the LupusCorner community to move autoimmune care from reactive to proactive.
Helix
Helix is a San Mateo-based population genomics company that helps health systems, life sciences companies, and public health organizations weave genomic data into everyday patient care. Built around its proprietary Exome+ assay and the first FDA-authorized whole exome sequencing platform, Helix powers large-scale precision health programs at partners like Mayo Clinic and Renown Health, with a research network spanning hundreds of thousands of sequenced participants.
BlueSphere Bio
BlueSphere Bio is a Pittsburgh-based clinical-stage biotechnology company developing personalized T-cell receptor (TCR) therapies for cancer. Spun out of the University of Pittsburgh and UPMC Enterprises in 2017, the company's proprietary TCXpress platform rapidly discovers and screens natural T-cell receptors that can target cancer antigens hidden inside cells - a reach beyond what conventional CAR-T therapies achieve. Its lead programs target high-risk hematologic malignancies such as relapsed/refractory acute myeloid leukemia.
Hone Health
Hone Health is a New York-based telemedicine clinic built for preventive and longevity care. It pairs at-home and in-person testing of 40+ biomarkers with physician-guided treatment plans for hormone optimization, menopause, weight loss, sexual health, thyroid and more, delivered nationwide on a subscription model starting around $129/month. After raising a $33M Series A in January 2025 and acquiring in-home care company ivee, Hone has tested 300,000+ patients and treats roughly 55,000 active members.
Kardigan
Kardigan is a South San Francisco heart health company modernizing cardiovascular drug development. Founded by the team behind MyoKardia, it pairs a late-stage clinical pipeline in dilated cardiomyopathy, acute severe hypertension and calcific aortic valve stenosis with a 'cardiac intelligence' platform - real-world patient data and AI - to match disease drivers to the right responders.
Fred Parietti
Fred Parietti (Federico) is the Co-Founder and CEO of Multiply Labs, a San Francisco-based robotics company building automated biomanufacturing infrastructure for next-generation pharmaceuticals. Armed with a PhD in robotics from MIT and a childhood passion for Legos, he bet his career on a contrarian thesis: that the highest-value application for advanced robotics wasn't pizza delivery or self-driving cars, but cell therapy manufacturing — where a single batch is worth $400K to $2 million and still made by hand. Multiply Labs has raised over $25 million and announced an $85 million partnership with Retro Biosciences, positioning itself to slash cell therapy costs by 70% and bring life-saving treatments to millions instead of thousands.